U.S. patent law will have to adapt to the use of AI in the life sciences industry.
Bruce M. Wexler
Advertisement
Articles by Bruce M. Wexler
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
AI has Redefined Healthcare Communication — and There’s No Opting Out
2
How FDA's Removal of the Two-Trial Requirement Affects Development Programs
3
FDA Grants Priority Review to Enhertu as Treatment for Patients with HER2-positive Early Breast Cancer
4
Senate Democrats Expand Efforts to Expose Details of MFN Pharma Deals
5